Information  X 
Enter a valid email address
  Print      Mail a friend       More announcements

Wednesday 04 December, 2019

BlackRock Group

Form 8.3 - Allergan PLC

RNS Number : 6878V
BlackRock Group
04 December 2019
 

Ap19

 

 

FORM 8.3

 

IRISH TAKEOVER PANEL

 

DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

 

DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

 

1.       KEY INFORMATION

 

Name of person dealing (Note 1)

BlackRock, Inc.

Company dealt in

Allergan plc

Class of relevant security to which the dealings being disclosed relate (Note

US$0.0001 ordinary shares

Date of dealing

03 December 2019

 

2.         INTERESTS AND SHORT POSITIONS

 

(a)        Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)

 

Long

Short

 

Number

 

(%)

Number

 

(%)

(1) Relevant securities

20,673,178 (6.29%)

59,228 (0.01%)

(2) Derivatives (other than options)

4,134,017 (1.25%)

52,000 (0.01%)

(3) Options and agreements to purchase/sell

0 (0.00%)

0 (0.00%)

Total

24,807,195 (7.55%)

111,228 (0.03%)

             

 

(b)        Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3)

Class of relevant security:

Long

Short

 

Number

 

(%)

Number

 

(%)

(1) Relevant securities

 

 

 

(2) Derivatives (other than options)

 

 

 

(3) Options and agreements to purchase/sell

 

 

Total

 

 

             

 

Ap20

 

 

1.       DEALINGS (Note 4)

 

(a)      Purchases and sales

 

 

 

Purchase/sale

 

Number of relevant securities

 

Price per unit (Note 5)

Purchase

317

USD 184.3400

Purchase

766

USD 184.7000

Purchase

182

USD 185.0900

Purchase

1,545

USD 185.3036

Sale

766

USD 184.7000

Sale

165

USD 184.7618

Sale

7,979

USD 185.0900

Sale

100

USD 185.2095

   

Please note: there was also a Transfer Out of 7,858 Shares

 

 

(b)      Derivatives transactions (other than options transactions)

 

Product name,

e.g. CFD

Nature of transaction

(Note 6)

Number of relevant securities

(Note 7)

Price per unit

(Note 5)

CFD

Increasing Long

57,487

USD 185.2571

CFD

Reducing Short

15

USD 185.2933

   

(c)      Options transactions in respect of existing relevant securities

 

 

(i)       Writing, selling, purchasing or varying

 

Product name,

e.g. call option

Writing, selling, purchasing, varying etc.

Number of securities to which the option relates (Note 7)

Exercise price

Type, e.g. American, European etc.

Expiry date

Option money paid/received per unit (Note 5)

 

 

 

 

 

 

 

 

(ii)      Exercising

 

Product name,

e.g. call option

Number of securities

Exercise price per unit (Note

 

 

 

 

(d)      Other dealings (including transactions in respect of new securities) (Note 4)

 

Nature of transaction

(Note 8)

Details

Price per unit

(if applicable) (Note 5)

Stock on Loan

766

N/A

Return of Stock on Loan

600

N/A

   

 

Ap21

 

2.       OTHER INFORMATION

 

Agreements, arrangements or understandings relating to options or derivatives

 

 

Full details of any agreement, arrangement or understanding between the person disclosing

and any other person relating to the voting rights of any relevant securities under any option

referred to on this form or relating to the voting rights or future acquisition or disposal of any 

relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.

 

 

 

None

 

 

 

Is a Supplemental Form 8 attached? (Note 9)                                    NO

 

Date of disclosure

04 December 2019

Contact name

Jana Blumenstein

Telephone number

+44 20 7743 3650

If a connected EFM, name of offeree/offeror with which connected

 

If a connected EFM, state nature of connection (Note 10)

 

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
ISEEAAALESSNFFF

a d v e r t i s e m e n t